Status: Currently Official on 14-Feb-2025
Official Date: Official as of 01-May-2020
Document Type: USP Monographs
DocId: GUID-5B945100-1603-4D7D-A9C3-9B013A9ACD2F_5_en-US
DOI: https://doi.org/10.31003/USPNF_M29708_05_01
DOI Ref: rn3ws

Eprinomectin



$C_{50}H_{75}NO_{14}$ (Component B_{1a}) 914.13
$C_{49}H_{73}NO_{14}$ (Component B_{1b}) 900.10

Component B_{1a}

Avermectin A_{1a}, 4"-(acetylamino)-5-*O*-demethyl-4"-deoxy-, (4"*R*)-; (2a*E*,4*E*,5'*S*,6*S*,6'*R*,7*S*,8*E*,11*R*,13*S*,15*S*,17a*R*,20*R*,20a*R*,20b*S*)-6'-(*S*)-*sec*-butyl-5',6,6',7,10,11,14,15,17a,20,20a,20b-dodecahydro-20,20b-dihydroxy-5',6,8,19-tetramethyl-17-oxospiro[11,15-methano-2*H*,13*H*,17*H*-furo[4,3,2-*pq*][2,6]benzodioxacyclooctadecin-13,2'-[2*H*]pyran]-7-yl-4-*O*-(4-acetamido-2,4,6-trideoxy-3-*O*-methyl-α-L-*lyxo*-hexopyranosyl)-2,6-dideoxy-3-*O*-methyl-α-L-*arabino*-hexopyranoside [or (4"*R*)-4"-(acetylamino)-5-*O*-demethyl-4"-deoxyavermectin A_{1a}] CAS RN®: 133305-88-1; UNII: 00OY54D31C.

Component B_{1b}

Avermectin A_{1a}, 4"-(acetylamino)-5-*O*-demethyl-25-de(1-methylpropyl)-4"-deoxy-25-(1-methylethyl)-, (4"*R*)-; (2a*E*,4*E*,5'*S*,6*S*,6'*R*,7*S*,8*E*,11*R*,13*S*,15*S*,17a*R*,20*R*,20a*R*,20b*S*)-5',6,6',7,10,11,14,15,17a,20,20a,20b-Dodecahydro-20,20b-dihydroxy-6'-isopropyl-5',6,8,19-tetramethyl-17-oxospiro[11,15-methano-2*H*,13*H*,17*H*-furo[4,3,2-*pq*][2,6]benzodioxacyclooctadecin-13,2'-[2*H*]pyran]-7-yl-4-*O*-(4-acetamido-2,4,6-trideoxy-3-*O*-methyl-α-L-*lyxo*-hexopyranosyl)-2,6-dideoxy-3-*O*-methyl-α-L-*arabino*-hexopyranoside [or (4"*R*)-4"-(acetylamino)-5-*O*-demethyl-25-de(1-methyl-propyl)-4"-deoxy-25-(1-methylethyl)avermectin A_{1a}] CAS RN®: 133305-89-2; UNII: 31OML2QZ0Q.

DEFINITION

Eprinomectin is a mixture of component B_{1a} ($C_{50}H_{75}NO_{14}$) and component B_{1b} ($C_{49}H_{73}NO_{14}$). It contains NLT 90.0% of component B_{1a} ($C_{50}H_{75}NO_{14}$) and NLT 95.0% of components B_{1a} ($C_{50}H_{75}NO_{14}$) and B_{1b} ($C_{49}H_{73}NO_{14}$), calculated on the anhydrous, solvent-free, and antioxidant-free basis. It may contain small amounts of a suitable antioxidant.

IDENTIFICATION

Change to read:

• **A.** ▲**Spectroscopic Identification Tests** ⟨197⟩, *Infrared Spectroscopy*: **197M**▲ (CN 1-May-2020)

• **B.** The retention times of the component B_{1a} peak and the component B_{1b} peak of the *Sample solution* correspond to those of the *Standard solution*, as obtained in the *Assay*.

ASSAY

• **Procedure**

Solution A: 0.1% (v/v) solution of perchloric acid in water

Solution B: Acetonitrile

Mobile phase: See *Table 1*.

Table 1

Time (min)	Solution A (%)	Solution B (%)
0	45	55

Time (min)	Solution A (%)	Solution B (%)
15	45	55
25	5	95
30	45	55
35	45	55

Diluent: Methanol and water (4:1)

Standard solution: 0.500 mg/mL of USP Eprinomectin RS in *Diluent*

System suitability solution: Transfer 4 mL of *Standard solution* to an LC vial. Add 2 drops of 1 M sodium hydroxide and let stand for 20 min prior to injection.

Sample solution: 0.500 mg/mL of Eprinomectin in *Diluent*

Chromatographic system

(See *Chromatography ⟨621⟩, System Suitability*.)

Mode: LC

Detector: UV 245 nm

Column: 4.6-mm × 25-cm; 5-µm packing L7

Column temperature: 40°

Flow rate: 1.5 mL/min

Injection volume: 15 µL

System suitability

Samples: *Standard solution* and *System suitability solution*

[NOTE—For relative retention times, see *Table 2*.]

Table 2

Components of the System Suitability Solution	Relative Retention Time
Impurity A	0.55
Component B_{1b}	0.77
Component B_{1a}	1.00
Impurities C + D	1.05
Impurity E	1.28

Suitability requirements

Resolution: NLT 3 between component B_{1b} and component B_{1a}; NLT 1 between component B_{1a} and impurities C + D, *System suitability solution*

Column efficiency: NLT 4,500 theoretical plates for component B_{1a}, *System suitability solution*

Symmetry factor: NMT 1.5 for component B_{1a}, *System suitability solution*

Relative standard deviation: NMT 1.0% from five injections for component B_{1a}, *Standard solution*

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of component B_{1a} ($C_{50}H_{75}NO_{14}$) in the portion of Eprinomectin taken:

$$\text{Result} = [r_{1a}/(r_{1a} + r_{1b})] \times 100$$

r_{1a} = peak area of component B_{1a} from the *Sample solution*

r_{1b} = peak area of component B_{1b} from the *Sample solution*

Calculate the percentage of component B_{1a} ($C_{50}H_{75}NO_{14}$) and component B_{1b} ($C_{49}H_{73}NO_{14}$) in the portion of Eprinomectin taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak area of component B_{1a} or component B_{1b} from the *Sample solution*

r_S = peak area of component B_{1a} or component B_{1b} from the *Standard solution*

C_S = concentration of component B_{1a} or component B_{1b} in the *Standard solution* (mg/mL)

C_U = concentration of the *Sample solution* (mg/mL)

Acceptance criteria: NLT 90.0% of component B_{1a} and NLT 95.0% of components B_{1a} and B_{1b}, on the anhydrous, solvent-free, and antioxidant-free basis

IMPURITIES

• **Residue on Ignition ⟨281⟩:** NMT 0.1%

• **Limit of 8a-oxo-B_{1a}**

Solution A, Solution B, Diluent, Standard solution, System suitability solution, and **Sample solution:** Prepare as directed in the *Assay*.

Mobile phase: Acetonitrile and *Solution A* (13:7)

Butylated hydroxytoluene stock solution: 0.5 mg/mL of butylated hydroxytoluene in methanol. Sonicate to dissolve, if necessary.

Butylated hydroxytoluene solution: 0.01 mg/mL of butylated hydroxytoluene from *Butylated hydroxytoluene stock solution* in *Diluent*

Chromatographic system

(See *Chromatography ⟨621⟩, System Suitability*.)

Mode: LC

Detector: UV 280 nm

Column: 4.6-mm × 25-cm; 5-µm packing L7

Column temperature: 40°

Flow rate: 1.5 mL/min

Injection volume: 15 µL

System suitability 1

Samples: *Standard solution* and *System suitability solution*

System suitability determination: Use the conditions as directed for *Chromatographic system* and the suitability requirements for *System suitability* as directed in the *Assay*.

System suitability 2

Samples: *Sample solution* and *Butylated hydroxytoluene solution*

Suitability requirements

Relative standard deviation: NMT 3.0% from six injections, *Butylated hydroxytoluene solution*

Analysis

Samples: *Sample solution* and *Butylated hydroxytoluene solution*

[Note—The retention time for 8a-oxo-B_{1a} is 4–9 min from the *Sample solution*, and the retention time for butylated hydroxytoluene is 12–17 min from *Butylated hydroxytoluene solution*.]

Calculate the percentage of 8a-oxo-B_{1a}, on the anhydrous, solvent-free, and antioxidant-free basis in the portion of Eprinomectin taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times F \times P \times 100$$

r_U = peak area of 8a-oxo-B_{1a} from the *Sample solution*

r_S = peak area of butylated hydroxytoluene from the *Butylated hydroxytoluene solution*

C_S = concentration of butylated hydroxytoluene in the *Butylated hydroxytoluene solution* (mg/mL)

C_U = concentration of Eprinomectin in the *Sample solution* (mg/mL)

F = relative response factor for butylated hydroxytoluene with respect to 8a-oxo-B_{1a}, 0.4

P = purity of butylated hydroxytoluene used to prepare the *Butylated hydroxytoluene solution*

Acceptance criteria: NMT 0.5%

Change to read:

• **Organic Impurities**

Solution A, Solution B, Mobile phase, Diluent, Standard solution, System suitability solution, Sample solution, Chromatographic system, and **System suitability:** Proceed as directed in the *Assay*.

Analysis

Sample: *Sample solution*

Calculate the percentage of each impurity in the portion of Eprinomectin taken:

$$\text{Result} = (r_U/r_T) \times 100$$

r_U = peak area of each individual related substance from the *Sample solution*

r_T = sum of the responses of all the peaks

Acceptance criteria: [NOTE—See *Table 2* for the relative retention times of impurity A and impurity E.]

Impurities with relative retention times of 0.23, 0.93, and 1.16 with respect to the B_{1a} peak: NMT 1.0%

Impurity A: NMT 1.0%

Impurity E: NMT 1.0%

All other known impurities: NMT 0.5%

Total unknown impurities: NMT 1.0▲%▲ (ERR 1-Jun-2019)

Total impurities: NMT 5.0%

SPECIFIC TESTS

- **OPTICAL ROTATION** ⟨781S⟩, *Procedures, Specific Rotation*

Sample solution: 5 mg/mL of Eprinomectin in chloroform

Acceptance criteria: +132° to +140°, determined at 405 nm on the anhydrous, solvent-free, and antioxidant-free basis

- **WATER DETERMINATION** ⟨921⟩, *Method I, Method Ia*

Sample: 0.250 g

Acceptance criteria: NMT 2.0%

ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in tight containers, and store between 2° and 8° at ambient humidity.
- **LABELING:** Label it to state the name(s) and amount(s) of any added substance(s). Label to indicate that it is for veterinary use only.
- **USP REFERENCE STANDARDS** ⟨11⟩

USP Eprinomectin RS

Auxiliary Information - Please check for your question in the FAQs before contacting USP.

Topic/Question	Contact	Expert Committee
EPRINOMECTIN	Documentary Standards Support	SM32020 Small Molecules 3

Chromatographic Database Information: Chromatographic Database

Most Recently Appeared In:
Pharmacopeial Forum: Volume No. PF 42(4)

Current DocID: GUID-5B945100-1603-4D7D-A9C3-9B013A9ACD2F_5_en-US

DOI: https://doi.org/10.31003/USPNF_M29708_05_01

DOI ref: rn3ws